[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-functions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-functions":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,53,87,116,146,176,201,225,249],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":35,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100643122","the-effects-of-anesthesia-on-postoperative-cognitive-functions-in-patients-undergoing-sleeve-gastrectomy-100643122",false,"NCT07637357","The Effects of Anesthesia on Postoperative Cognitive Functions in Patients Undergoing Sleeve Gastrectomy","The Effects of Total Intravenous Anesthesia and Inhalational Anesthesia on Postoperative Cognitive Functions in Patients Undergoing Sleeve Gastrectomy","Inclusion Criteria:\n\nPatients of both sexes, Patients Aged between 18 and 65 years, Patients classified as ASA(American Society of Anesthesiologists) physical status I- III, Patients with a BMI (Body Mass Index) between 35 and 50 kg\u002Fm² scheduled to undergo sleeve gastrectomy as a type of bariatric surgery for the first time.\n\nExclusion Criteria:\n\nPatients classified as ASA physical status 4 or high, Patients with known allergy to any of the drugs used in the study, Patients with bleeding disorders, Patients with serum creatinine levels \\>2 mg\u002FdL, Patients with severe arrhythmias and EF\\\u003C30%, Patients with a known history of drug abuse are excluded.","ALL","18 Years","65 Years",{"count":20,"type":21},60,"ESTIMATED","3 Months","OBSERVATIONAL","In this study, the investigators want to examine the effects of intravenous anesthetic drugs and gases on cognitive functions in the postoperative period in individuals who will undergo surgery for obesity. The investigators believe that the anesthesia method we apply with inhalation gases is also as reliable method as total intravenous anesthesia for postoperative cognitive functions in these patients who undergoe sleeve gastrectomy.\n\nThe anesthesia method applied intravenously and with inahalational gases have been applied safely for many years. Comparisons between these two anesthesia technics in obese individuals and for postoperative cognitive dysfunctions are limited.\n\nStudies on the examination of cognitive functions in postoperative patients have gained momentum with the use of neuropsychiatric tests performed on patients who have undergone cardiac surgery and these tests have also been performed on individuals who have undergone non-cardiac surgery. And yet, similar declines in cognitive functions have been observed. For these reasons, the effects of surgery itself and anesthesia methods on cognitive functions have been studied up to date.\n\nIn this study, the investigators plan to evaluate patients who will undergo obesity surgery in both anesthesia methods by the recovery times from anesthesia and the residual effects of anesthesia, and after awakening they plan to evaluate their cognitive functions with neuropsychiatric tests that will be performed at certain intervals.",[26,27,28,29,30,31,32,33,34],"POCD - Postoperative Cognitive Dysfunction","Recovery Time","Postoperative Neurocognitive Disorder","Postoperative Delirium","Bariatric Sleeve Gastrectomy","Delayed Neurocognitive Recovery","Total Intravenous Anesthesia","Inhalational Anesthesia","Cognitive Functions",[36,37,38,39],"total intravenous anesthesia","inhalational anesthesia","sleeve gastrectomy","postoperative cognitive dysfunctions","RECRUITING","2026-06-04",{"date":43,"type":44},"2026-06-09","ACTUAL",{"date":46,"type":44},"2025-09-30",{"date":48,"type":21},"2026-07-30",{"name":50,"class":51},"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":60,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":73,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":52},"100607902","phase-2-equol-and-vascular-function-in-women-with-chronic-kidney-disease-100607902","NCT07194590","Equol and Vascular Function in Women With Chronic Kidney Disease","Equol Supplementation for Improving Vascular Function in Postmenopausal Women With CKD","Inclusion Criteria:\n\n* Postmenopausal women\n* Aged ≥50 years\n* CKD stage 3 or 4 (eGFR with the CKD-EPI 2021 race-free equation: 15-59 mL\u002Fmin\u002F1.73m2; stable renal function in the past 3 months)\n* Low habitual intake of soy (soy-related food intake \\\u003C 2 times per week assessed by Soy-Specific Food Frequency Questionnaire)\n* Weight stable in the prior 3 months (\\\u003C2 kg weight change) and willing to remain weight stable throughout the study\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with advanced CKD requiring chronic dialysis\n* Uncontrolled hypertension in CKD group (BP \\>140\u002F90 mmHg)\n* Use of any hormone replacement therapy\n* Allergy and\u002For intolerance to soy or soy-based products\n* Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin values 2X upper limit of normal range (upper limit of normal range AST: 117 U\u002FL; ALT: 52 U\u002FL; total bilirubin: 1.3 mg\u002FdL)\n* History of breast cancer\n* Significant co-morbid conditions with a life expectancy of \\\u003C 1 year\n* Current tobacco or nicotine use or history of use in the last 12 months\n* History of kidney transplant\n* History of severe congestive heart failure (i.e., ejection fraction \\\u003C35%)\n* History of hospitalization within the last month\n* Immunosuppressant agents taken in the past 12 months\n* Known malignancy","FEMALE","50 Years",{"count":63,"type":21},74,"INTERVENTIONAL",[66],"PHASE2","The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH.\n\nEquol contributes to improvement in vascular function, mediated in part by its anti-oxidative and anti-inflammatory properties. However, there is no information on the effect of equol on vascular function in women with CKD. The proposed project aims to determine the effect of 12 weeks of oral equol supplementation on vascular function in postmenopausal women with CKD.",[69,70,34,71,72],"Chronic Kidney Disease (Stage 3-4)","Vascular Function","Cerebrovascular Function","Blood Pressure",[74,75,76,77,70],"S-equol","Randomized Controlled Trial","Chronic Kidney Disease","Women's Health","2026-06-01",{"date":80,"type":44},"2026-06-02",{"date":82,"type":44},"2026-02-19",{"date":84,"type":21},"2030-11-30",{"name":86,"class":51},"University of Colorado, Denver",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":16,"minAge":17,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":52},"100622758","sleep-quality-and-cognitive-functions-in-adults-a-cross-sectional-study-100622758","NCT07387783","Sleep Quality and Cognitive Functions in Adults: A Cross-Sectional Study","The Association Between Sleep Quality and Cognitive Functions in Healthy Young Adults","Inclusion Criteria:\n\n* Between 18 and 35 years.\n* Ability and willingness to provide written informed consent.\n* Sufficient ability to read, understand, and communicate in Turkish, the language in which the assessments are administered.\n* Self-reported good general health, with no active medical or psychiatric conditions that significantly affect daily functioning.\n* Willingness and ability to wear a wearable sleep monitoring device continuously for five consecutive days and to comply with device usage instructions.\n* Ability to attend and complete a single-session cognitive assessment\n\nExclusion Criteria:\n\n* Regular or frequent use of medications known to affect sleep or cognitive function, including sedative-hypnotics, benzodiazepines, antipsychotics, stimulants, opioids, or similar agents.\n* Initiation of, or dose changes in, psychotropic medications within the past four weeks.\n* Being under the influence of alcohol or illicit substances on the day of cognitive testing.\n* Engagement in night shift work or rotating shift schedules within the past one month.\n* Travel across time zones resulting in a time difference of two hours or more within the past two weeks.\n* Uncontrolled high daily intake of caffeine (e.g., \\>400 mg\u002Fday) and unwillingness to reduce consumption during the study period.\n* Color blindness or other color vision deficiencies, due to their potential impact on Stroop Test performance.\n* Dermatological conditions, allergies, or skin lesions at the wrist that prevent wearing the device, or refusal to wear the device as required.\n* Acute illness within the past two weeks, including febrile infections, severe pain, or other acute medical conditions that may temporarily affect sleep or cognitive performance.\n* Pregnancy or early postpartum period.",true,"35 Years",{"count":97,"type":21},75,"This observational cross-sectional study aims to examine the association between sleep quality and cognitive functions in healthy young adults. Subjective sleep quality will be assessed using the Pittsburgh Sleep Quality Index, and objective sleep parameters will be collected using a wearable device over five consecutive days. Cognitive functions will be evaluated at a single assessment session using standardized neuropsychological tests, including measures of attention, executive functions, and verbal memory. The study seeks to explore relationships between subjective and objective sleep measures and cognitive performance. Findings from this study may contribute to a better understanding of how sleep quality is associated with cognitive functioning in healthy young adults.",[100,34],"Sleep Quality",[102,103,104,105,106],"sleep quality","Cognitive Function","Young Adults","verbal memory","wearable device","2026-04-27",{"date":109,"type":44},"2026-04-29",{"date":111,"type":44},"2026-01-26",{"date":113,"type":21},"2026-08",{"name":115,"class":51},"Uskudar University",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":94,"sex":16,"minAge":124,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":64,"phases":127,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":52},"100621549","cognitive-stimulation-therapy-group-for-residential-home-residents-with-dementia-and-mild-cognitive-impairment-100621549","NCT07372066","Cognitive Stimulation Therapy Group for Residential Home Residents With Dementia and Mild Cognitive Impairment","Effectiveness of Cognitive Stimulation Therapy Group for Residential Home Residents With Dementia and Mild Cognitive Impairment-- A Randomized Controlled Trial","CSTSAGE","Inclusion Criteria:\n\n1. age 60 years or older;\n2. diagnosis of MCI or dementia according to the Diagnostic and Statistical Manual of Mental Disorder (Fifth edition, Text Revision).\n\nRemark: Participants who do not receive a diagnosis of MCI or dementia will undergo a screening assessment by a researcher using the Chinese Montreal Cognitive Assessment (MoCA)-5 minutes.\n\nExclusion Criteria:\n\nThose who are unable to participate independently in group activities, who exhibit disruptive behavior and\u002For are severely impaired by physical disabilities (e.g. severe hearing and visual impairment) and physical illnesses (e.g. frequent hospital stays) are excluded.","60 Years",{"count":126,"type":21},110,[128],"NA","The research aims to investigate the effectiveness a cognitive stimulation therapy group for older adults with dementia and mild cognitive impairment living in residential homes.\n\nThis study adopts a multicenter randomized control trial two arms research design. The randomized controlled trial will compare a typical 14-session cognitive stimulation therapy group with a calligraphy group to determine whether the 14-session cognitive stimulation therapy group can produce better intervention outcomes for older adults with dementia and mild cognitive impairment, including cognitive functions, depressive symptoms, activities engagement, social functioning and, quality of life.",[34],[132,133,134,135,136],"Cognitive Stimulation Therapy","Calligraphy group","Randomized Controlled trial","Mild cognitive impairment","Dementia","2026-04-21",{"date":139,"type":44},"2026-04-24",{"date":141,"type":44},"2026-01-01",{"date":143,"type":21},"2026-09-30",{"name":145,"class":51},"City University of Hong Kong",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":154,"targetDuration":156,"studyType":23,"phases":4,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":52},"100620953","cognitive-function-in-obstructive-sleep-apnea-100620953","NCT07364318","Cognitive Function in Obstructive Sleep Apnea","Cognitive Function and Pathophysiological Mechanisms in Adults With Obstructive Sleep Apnea: Long-term Impact of Positive Airway Pressure Therapy","CUFM1DN","Inclusion Criteria:\n\n1. Informed consent.\n2. Age 18 - 65 years.\n3. Newly diagnosed OSA according to the criteria of the American Academy of Sleep Medicine Guidelines (overnight PSG with an AHI ≥5 events per hour, hypopneas defined by ≥ 10 seconds of airflow reduction accompanied by ≥ 3% desaturation or an arousal).\n4. Able to accomplish relevant tests and follow-up.\n\nExclusion Criteria:\n\n1. History of any chronic disease other than overweight and obesity.\n2. Severe psychiatric condition that could affect cognitive functions.\n3. Chronic use of medication or nicotine that may affect the study results.\n4. Prior neuropsychological assessment less than 6 months before the start of the research.\n5. Prior therapy for OSA (i.e., CPAP, upper airway surgery, or oral appliance).\n6. Motor or sensory deficits that would significantly complicate test administration.\n7. Patients who do not have Slovak as their native language actively used in daily communication.\n8. Considered by the study team as not suitable for enrollment based on clinical judgment.",{"count":155,"type":21},30,"12 Months","Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder and has been increasingly recognized as a contributor to cognitive decline and a potential risk factor for neurodegeneration. Previous studies have identified several associated comorbidities, including vascular dysfunction, metabolic alterations, and neuroinflammatory changes. However, the impact and underlying interplay of these pathophysiological mechanisms remain poorly understood due to the lack of integrated, multidimensional assessment. This prospective, observational, longitudinal cohort study aims to investigate cognition and OSA-related physiological and pathophysiological processes in 100 adults newly diagnosed with OSA, who have no history of chronic diseases (except for overweight and obesity) and are not receiving chronic medication. A subgroup of patients with moderate to severe OSA indicated for positive airway pressure (PAP) therapy will be followed to evaluate its long-term effects on cognitive function and related mechanisms. All participants will undergo polysomnography (PSG), comprehensive neuropsychological assessment, brain MRI with volumetric analysis, biomarker profiling from blood and saliva, and evaluation of endothelial function, baroreflex sensitivity, and gut microbiome composition at baseline and after 12 months. PAP adherence will be continuously monitored. The primary objective of this study is to characterize the profile of cognitive impairment associated with OSA. Secondary exploratory analyses will focus on factors contributing to neurocognitive dysfunction in OSA.",[159,34],"OSA - Obstructive Sleep Apnea",[103,161,162,163,164,165,166],"Positive Airway Pressure Therapy","Obstructive Sleep Apnea","Neuroimaging","Biomarkers","Vascular Changes","Metabolic Changes","2026-01-15",{"date":169,"type":44},"2026-01-23",{"date":171,"type":44},"2024-11-01",{"date":173,"type":21},"2027-12-31",{"name":175,"class":51},"Comenius University",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":184,"targetDuration":186,"studyType":23,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":4},"100619325","multimodal-brain-function-in-migraine-patients-with-patent-foramen-ovale-100619325","NCT07343154","Multimodal Brain Function in Migraine Patients With Patent Foramen Ovale","A Prospective Study on the Effects of Percutaneous Patent Foramen Ovale Closure on Multimodal Brain Function, Cognition, and Emotion in Patients With Migraine and Patent Foramen Ovale","NEURO-PFO","Inclusion Criteria:\n\n* Age ≥18 years and \\\u003C60 years at Screening\u002FBaseline.\n* Diagnosis of migraine with aura established by a neurologist according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria.\n* Migraine history ≥1 year AND, during the 3-month screening\u002Frun-in period, an average of ≥4 migraine days per month; participant is willing and able to complete a headache diary, which will be reviewed by the investigator prior to enrollment.\n* Patent foramen ovale (PFO) identified by transthoracic echocardiography (TTE) and confirmed by contrast transesophageal echocardiography (cTEE), with at least moderate atrial-level right-to-left shunt (RLS) during Valsalva maneuver.\n* RLS grading by microbubbles in the left-sided cardiac chambers per frame on single-frame images:\n* No RLS: 0 microbubbles\n* Grade I (small): 1-10 microbubbles\u002Fframe\n* Grade II (moderate): 11-30 microbubbles\u002Fframe\n* Grade III (large): \\>30 microbubbles\u002Fframe or near-complete opacification of the left chambers (\"hazy\" appearance)\n* Prior use of at least three different classes of migraine preventive therapies with either \\\u003C50% improvement in migraine frequency during treatment OR intolerable adverse effects.\n* At least two therapies must be from different categories among (a-f); the third may be one of (g-j):\n\n  1. Beta-blockers\n  2. Tricyclic antidepressants\n  3. Verapamil or flunarizine\n  4. Sodium valproate (or divalproex sodium)\n  5. Topiramate\n  6. Other anticonvulsants\n  7. Any therapy supported as effective by at least one positive randomized controlled trial\n  8. Nonsteroidal anti-inflammatory drugs (NSAIDs)\n  9. Metabolic agents (e.g., vitamin B2 or coenzyme Q10)\n  10. Traditional Chinese medicine\n* Participant has been on a stable daily dose regimen of preventive headache medication for ≥3 consecutive months prior to enrollment (to be verified during screening).\n* Written informed consent provided and willingness to comply with study procedures and follow-up schedule.\n\nExclusion Criteria:\n\n* Expected life expectancy ≤1 year at Screening\u002FBaseline.\n* Secondary migraine attributable to other causes.\n* History of transient ischemic attack (TIA), stroke, or intracranial hemorrhage.\n* Investigator-determined anatomical findings on TEE that are unfavorable for successful PFO occluder deployment or any contraindication to device implantation, including (but not limited to):\n* Inability to undergo\u002Fcomplete TEE\n* Vascular access unable to accommodate the delivery system\n* Requirement for transseptal puncture\n* Requirement for implantation of more than one occluder\n* Defect size estimated too large for successful closure\n* Potential interference between the occluder and other intracardiac structures\n* Anatomy preventing adequate apposition of the occluder discs to the atrial septum\n* Allergy to any component\u002Fmaterial of the AMPLATZER™ PFO Occluder (e.g., nickel allergy).\n* Current or past diagnosis of severe psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depressive disorder), or unstable psychiatric illness defined as psychiatric hospitalization, medication dose adjustment, or marked symptom fluctuation within the past 6 months.\n* Neurological and\u002For neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis), uncontrolled epilepsy\u002Fseizures within the past 1 year, central nervous system tumor, or history of traumatic brain injury.\n* History of myocardial infarction.\n* History of pacemaker implantation, atrial septal defect (ASD) closure, or left atrial appendage (LAA) closure.\n* Intracardiac right-to-left shunt due to causes other than PFO.\n* Contraindications to aspirin and\u002For clopidogrel, including significant thrombocytopenia, major trauma, acute clinically significant bleeding, or allergy to study medications.\n* Hepatic impairment defined as PT and\u002For APTT \\>2× the upper limit of normal (ULN) OR total bilirubin ≥3 mg\u002FdL.\n* Poorly controlled diabetes mellitus at Screening\u002FBaseline (as judged by the investigator).\n* Poorly controlled atrial fibrillation at Screening\u002FBaseline (as judged by the investigator).\n* Poorly controlled hypertension at Screening\u002FBaseline, defined as blood pressure \\>160\u002F90 mmHg despite appropriate pharmacologic treatment.\n* Active autoimmune disease at Screening\u002FBaseline (e.g., systemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, central nervous system granulomatous vasculitis).\n* Active infection at Screening\u002FBaseline that cannot be fully resolved prior to enrollment.\n* Alcohol abuse or drug dependence at Screening\u002FBaseline.\n* Ongoing anticoagulation therapy that cannot be discontinued.\n* Unable to accurately describe headache status and\u002For unable to complete\u002Fmaintain a headache diary.\n* Currently participating in another device or drug clinical trial in which the primary endpoint has not been reached, or that may clinically confound this study's endpoints, or that prohibits co-enrollment.\n* Pregnant or planning pregnancy during the study period.\n* Planned elective surgery during the study period.\n* Any medical condition or circumstance that, in the investigator's opinion, poses a significant risk to participant safety, confounds study results, or interferes with study participation.\n* Any other medical or non-medical reason that, in the investigator's opinion, makes the participant unsuitable (e.g., inability to comply with study procedures\u002Fvisits, plans to relocate during the study period).",{"count":185,"type":21},45,"3 Years","This investigator-initiated, single-center prospective study is designed to clarify how patent foramen ovale (PFO) relates to brain function abnormalities in patients with drug-refractory migraine with aura (MA), and whether percutaneous PFO closure is associated with measurable, longitudinal improvements in neurophysiological and neuroimaging markers as well as clinical symptoms.\n\nThe study addresses two core questions: (1) Do MA patients with clinically significant right-to-left shunt due to PFO demonstrate distinct resting-state brain function patterns-captured by high-density EEG (hdEEG), resting-state functional MRI (rs-fMRI), and standardized cognitive testing-compared with MA patients without PFO? (2) In MA patients with PFO who undergo clinically indicated percutaneous PFO closure, do these multimodal brain function measures change over time after closure (pre-procedure vs 1, 6, and 12 months), and are such changes accompanied by improvement in migraine burden, quality of life, and mood\u002Fanxiety symptoms? The protocol includes two phases. In Phase 1 (cross-sectional comparison), two groups are evaluated at baseline: MA with PFO (PFO+\u002FMA+) and MA without PFO (PFO-\u002FMA+). Participants complete hdEEG and rs-fMRI to characterize whole-brain power spectral density and connectivity, and undergo MATRICS Consensus Cognitive Battery (MCCB) testing and validated symptom\u002Fpsychological assessments (e.g., MIDAS, MSQ v2.1, PHQ-9, GAD-7, RoPE). In Phase 2 (prospective self-controlled cohort), eligible PFO+\u002FMA+ participants who proceed to percutaneous PFO closure as part of routine clinical care are followed longitudinally with repeated multimodal assessments at pre-closure baseline and post-closure 1, 6, and 12 months. This phase evaluates within-person trajectories of resting-state brain function (hdEEG, rs-fMRI) and cognition\u002Femotion measures, together with migraine diary-based outcomes and patient-reported quality of life\u002Fdisability and mood\u002Fanxiety scales. Key eligibility focuses on adults aged 18-65 years with ICHD-3-defined migraine with aura and a history of frequent migraine (≥4 migraine days\u002Fmonth during screening) despite prior preventive therapy trials; the PFO group requires echocardiographic confirmation of PFO with at least moderate right-to-left shunt (e.g., during Valsalva on contrast TEE), consistent with the study's focus on clinically meaningful shunt physiology.\n\nThe primary endpoints are multimodal brain function and cognition measures. In Phase 1, the main outcomes include between-group differences in MCCB composite score, rs-fMRI whole-brain functional connectivity strength, and hdEEG spectral power across frequency bands (delta\u002Ftheta\u002Falpha\u002Fbeta\u002Fgamma) and theta-band connectivity quantified by whole-brain phase-lag index (PLI). In Phase 2, the primary outcome is the 12-month post-closure change in these multimodal resting-state brain function measures, reflecting dynamic neural recovery or reorganization after PFO closure.\n\nSecondary outcomes include changes in migraine clinical metrics (monthly migraine days, attack frequency and duration, and complete remission rate), migraine-specific quality of life (MSQ v2.1), disability (MIDAS), and depression\u002Fanxiety symptom scores (PHQ-9 and GAD-7) over follow-up. Safety outcomes include adverse events potentially related to the closure procedure and routine post-procedural anti-thrombotic therapy, captured throughout follow-up.",[189,190,34,191],"PFO","Cognitive","Migraine","NOT_YET_RECRUITING","2026-01-06",{"date":167,"type":44},{"date":196,"type":21},"2026-02-01",{"date":198,"type":21},"2029-06-30",{"name":200,"class":51},"Second Xiangya Hospital of Central South University",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":64,"phases":212,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":4},"100614830","phase-3-phenolic-complex-k110-42-therapy-on-cognitive-functions-in-down-children-100614830","NCT07284693","Phenolic Complex k110-42 Therapy on Cognitive Functions in Down Children","Clinical Study Evaluating the Efficacy of Phenolic Complex k110-42 Therapy on Cognitive Functions of Children With Down Syndrome","Inclusion Criteria:\n\n* Children diagnosed with Down syndrome (Non disjunction Trisomy 21) based on genetic testing .\n* Age between 4-8 years old .\n* Down syndrome children presented with difficulties in attention or focus as reported by parents or based on prior clinical assessments.\n\nExclusion Criteria:\n\n* Parents' refusal.\n* Down syndrome children with other significant developmental or neurological disorders (e.g., autism spectrum disorder, epilepsy).\n* Patients with any chronic illness as liver or renal dysfunction; inflammatory diseases; autoimmune disease; cancer, acute cardiovascular event, eating disorders (anorexia, bulimia) or gastrointestinal disorders.\n* Presence of hypersensitivity to spearmint or any components of Neumentix (Neumentix may increase kidney or liver damage if used in large amounts).\n* Use of stimulant ADHD medication or cognitive-enhancing supplements .\n* IQ test less than 55%.\n* Patients with hypothyroidism.","4 Years","8 Years",{"count":211,"type":21},108,[213],"PHASE3","The goal of this study is to evaluate the efficacy of phenolic complex k110-42 on cognitive function of children with Down syndrome",[34],"2025-12-14",{"date":218,"type":44},"2025-12-16",{"date":220,"type":21},"2026-01",{"date":222,"type":21},"2026-12",{"name":224,"class":51},"Mansoura University",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":94,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":64,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":52},"100570498","evaluation-of-a-home-based-aomi-intervention-on-cognitive-function-and-depression-among-adults-with-sci-100570498","NCT06708026","Evaluation of a Home-based AOMI Intervention on Cognitive Function and Depression Among Adults with SCI","Evaluation of a Home-based Action Observation and Motor Imagery Intervention on Cognitive Function and Depression Among Adults with Spinal Cord Injury: a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosis of SCI according to the International Standards for the Neurological Classification of SCI with confirmation by computed tomography\u002Fmagnetic resonance imaging;\n* At least 18 years old;\n* With stable spinal systems and good vital signs, and currently living in the community and having SCI for more than 6 months;\n* No contraindications to undergoing MRI examination (e.g., no metal or electronic devices in the body, not pregnant, and absence of claustrophobia);\n* Having a mobile Internet terminal (usually a smartphone) and proficient independent or caregiver-assisted usage;\n* Able to communicate in Cantonese and to provide informed consent.\n\nExclusion Criteria:\n\n* Having severe problems in hearing, verbal communication, or vision;\n* Engaged in ongoing psychotherapy or any other physiotherapy\u002F exercise\u002F relaxation interventions;\n* Physically active for more than 150 minutes moderate-intensity exercise per week;\n* Diagnosis of mental disorders or substance misuse;\n* With severe cognitive impairment (Hong Kong Montreal Cognitive Assessment (HK-MoCA) score ≤ 18.",{"count":233,"type":21},46,[128],"The investigators propose a pilot randomized clinical trial to determine if adults with spinal cord injury (SCI) show improved cognitive function and depression following home-based Action Observation and Motor Imagery (AOMI) training. It is hypothesized that the home-based AOMI intervention will show satisfactory feasibility and acceptability. They also hypothesize that AOMI training can be used as a rehabilitative tool for improving cognitive function and depression in adults with SCI, because it engages and strengthens similar neural systems as actual exercise.",[237,238,239,34],"Spinal Cord Injuries (SCI)","Depression","Motor Imagery","2025-02-03",{"date":242,"type":44},"2025-02-06",{"date":244,"type":21},"2025-03-01",{"date":246,"type":21},"2026-06-30",{"name":248,"class":51},"The Hong Kong Polytechnic University",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":60,"minAge":256,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":260,"conditions":261,"keywords":266,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":278},"100348141","neuropsychological-assessment-of-children-and-adolescents-with-turner-syndrome-100348141","NCT03812913","Neuropsychological Assessment of Children and Adolescents With Turner Syndrome","ENEAST","INCLUSION CRITERIA\n\nTurner syndrome group :\n\n* girls with diagnosed Turner syndrome.\n\nIsolated GHD group :\n\n* girls with diagnosed isolated growth hormone deficiency\n\nAll participants :\n\n* age between 7 years to 16 years and 11 months.\n* informed consent signed by the participant and her parents (or her legal representatives)\n* being registered in the national social security system\n\nEXCLUSION CRITERIA :\n\nTurner syndrome group :\n\n* patients with chronic pathology other than Turner syndrome.\n* karyotype : part of a Y chromosome and r(X) cases.\n* medical treatment other than those usually prescribed in patients with Turner syndrome.\n\nIsolated GHD group :\n\n* patients with chronic pathology other than isolated growth hormone deficiency.\n* medical treatment other than those usually prescribed in patients with isolated growth hormone deficiency.\n\nAll participants :\n\n* diagnosed intellectual disability (IQ\\\u003C70) or intellectual giftedness\n* history of acquired brain injury\n* sensory disturbances (auditory or visual) incompatible with the achievement of neuropsychological tasks.\n* insufficient French language proficiency","7 Years","16 Years",{"count":259,"type":21},70,"Turner syndrome (TS) is a rare chromosomal disorder characterized by partial or complete loss of one of the X chromosomes that affects about one in every 2000 female babies born. These young patients described difficulties making friends, understanding others' emotions and intentions, and controlling their own emotions. Difficulties in these domains could led to social withdrawal, to reduced social skills and could have a significant impact on self esteem and mental health as well as on long-term academic and social functioning in affected individuals. The purpose of this project is to identify functional and dysfunctional cognitive and socio-cognitive abilities in these young patients which could account social difficulties described by some of them and their family. To this end, 35 girls with TS and 35 girls with isolated growth hormone deficiency and normal cerebral MRI will be recruited. Subjects will be 7 to 16 years and 11 months of age. Socio-cognitive and cognitive functions will be assessed with neuropsychological and experimental tasks. Questionnaires completed by patient, parents or teacher, will evaluate social and behavioral functioning.",[262,263,34,264,265],"Turner Syndrome","Isolated Growth Hormone Deficiency","Social Cognition","Pediatrics",[267,34,264,265],"Turner syndrome","2024-12-26",{"date":270,"type":44},"2024-12-30",{"date":272,"type":44},"2019-09-05",{"date":274,"type":21},"2025-12-05",{"name":276,"class":277},"University Hospital, Angers","OTHER_GOV",3]